TLC and Nippon Zoki sign NT$6.5B contract for osteoarthritis drug｜Formosa English News

Bilingual text here: https://english.ftvnews.com.tw/news/2026B02W0AEA?utm_source=youtube&utm_medium=description 雙語文字版: https://english.ftvnews.com.tw/news/2026B02W0AEA?utm_source=youtube&utm_medium=description Our official website: ➔ https://english.ftvnews.com.tw/ Follow us on Facebook: ➔ https://www.facebook.com/ftvformosanews X (Twitter): ➔ https://x.com/FTV_Taiwan_News Taiwan and Japan ties just got stronger! Taiwanese biotech company, TLC produced a brand new injection called TLC599, to treat osteoarthritis pain. On Thursday, a partnership ceremony was held with Japanese pharma company, Nippon Zoki. The exclusive licensing agreement between the two companies is worth approximately NT$6.5 billion. The ceremony was attended by Minister of Health and several representatives from the Japan-Taiwan Exchange Association. Taiwan and Japan’s medical partnership grows stronger. TLC and Nippon Zoki announced a new agreement on the drug TLC599, bringing a new treatment option to treat osteoarthritis pain in Japanese patients. Several Japan-Taiwan representatives attended the event as well as Taiwan’s Minister of Health Shih Chung-liang. They witnessed the signing of the exclusive licensing agreement which is worth around NT$6.5 billion. This collaboration with a 90-year-old Japanese company will promote the treatment in Japan. George Yeh CEO of TLC Nippon Zoki actually focuses on pain and joints. There’s also a very good sales channel for the product, which will let TLC599 enter the Japanese market faster. Takafumi Konishi President & CEO of Nippon Zoki In Japan’s aging society there are many patients who deeply suffer from osteoarthritis of the knee. We hope that from today onwards, we can use all our efforts to contribute to this field. We want to thank everyone who made this contract signing possible. The health condition of osteoarthritis doesn’t just affect the elderly; it also affects many middle-aged and young adults. Statistics show that there are over 25 million patients in Japan who are over 40-years-old, from which 8 million experience painful symptoms, which could limit daily walking to basic activities ultimately affecting their quality of life. George Yeh CEO of TLC Japan’s medical market, is around the 10th biggest in the world, so this is a very good benchmark to see if this product could have a breakthrough in European or American markets as well. The TLC599, beyond relieving pain for patients suffering from osteoarthritis, also promotes transnational cooperation, strengthening ties between Taiwan and Japan. For more Taiwan news, tune in: Mon to Fri at 9:30 pm on Channel 152 Tue to Sat at 1 am on Channel 53 #medical #tlc599 #osteoarthritis #TLC #japan #nipponzaki #taiwanmedicine #台灣新聞 #FormosaEnglishNews #民視新聞 #FTV新聞 #Taiwan